Back to Studies
IMPAACT 2050
Phase IV Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1
Primary Protocol Team Members
Summary
IMPAACT 2050 is a Phase IV study designed to characterize the pharmacokinetics and safety of long-acting injectable cabotegravir (CAB) and rilpivirine (RPV) used in a clinical care setting to treat women living with HIV-1 during pregnancy and postpartum. Women will be followed during pregnancy and then together with their infants through six weeks postpartum.
Site selection is ongoing and is open to US-based IMPAACT sites only, due to the current market availability of long-acting CAB and RPV.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...